Read by QxMD icon Read

mCRPC prognosis nomogram

Yun-Jie Yang, Guo-Wen Lin, Gao-Xiang Li, Bo Dai, Ding-Wei Ye, Jun-Long Wu, Hu-Yang Xie, Yao Zhu
Abiraterone acetate is approved for the treatment of castration-resistant prostate cancer (CRPC); however, its effects vary. An accurate prediction model to identify patient groups that will benefit from abiraterone treatment is therefore urgently required. The Chi model exhibits a good profile for risk classification, although its utility for the chemotherapy-naive group is unclear. This study aimed to externally validate the Chi model and develop a new nomogram to predict overall survival (OS). We retrospectively analyzed a cohort of 110 patients...
March 2018: Asian Journal of Andrology
Junlong Wu, Guowen Lin, Yao Zhu, Hailiang Zhang, Guohai Shi, Yijun Shen, Yiping Zhu, Bo Dai, Dingwei Ye
T cell immunoglobulin 3 (TIM3) is a cell surface star molecule expressed on T cells, and also marks dysfunctional CD8(+) T cells in various kinds of cancers. However, there are few studies focusing on the expression of TIM3 in tumor cells. In our study, we recruited 139 patients with metastatic prostate cancer (mPCa) who received transurethral resection of the prostate (TURP) consecutively to examine whether TIM3 expression level is associated with overall survival (OS) in mPCa patients. Immunohistochemistry was performed to determine TIM3 expression in prostate cancer tissues and then patients were divided into two groups...
August 21, 2017: Scientific Reports
Robert J van Soest, Jason A Efstathiou, Cora N Sternberg, Bertand Tombal
CONTEXT: Biomarkers for the treatment of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed by clinicians to facilitate treatment decisions. OBJECTIVE: To review current prognostic and predictive biomarkers in mCRPC. EVIDENCE ACQUISITION: We performed a nonsystematic review of the literature from 2004 to August 2016 by searching in Medline. Cross-matching references were used to search for additional articles. We reviewed clinical research and review articles written in the English language...
December 2016: European Urology Focus
D Lorente, J Mateo, A J Templeton, Z Zafeiriou, D Bianchini, R Ferraldeschi, A Bahl, L Shen, Z Su, O Sartor, J S de Bono
BACKGROUND: The neutrophil-lymphocyte ratio (NLR), proposed as an indicator of cancer-related inflammation, has known prognostic value in prostate cancer. We examine its association with survival (OS) and response in patients treated with second-line chemotherapy. METHODS: We analysed patients with metastatic castration-resistant prostate cancer (mCRPC) treated in the TROPIC trial, evaluating cabazitaxel versus mitoxantrone. Cox regression models were used to investigate the association of baseline NLR (BLNLR) with OS and the significance of a change in NLR count with treatment...
April 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
R J van Soest, A J Templeton, F E Vera-Badillo, F Mercier, G Sonpavde, E Amir, B Tombal, M Rosenthal, M A Eisenberger, I F Tannock, R de Wit
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR), a marker of host inflammation, has been associated with poor outcome in several solid tumors. Here, we investigated associations of the derived NLR (dNLR) and duration of initial androgen deprivation therapy (ADT) with survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy. PATIENTS AND METHODS: Data from the multinational randomized phase III studies VENICE and TAX327 included a total of 2230 men with mCRPC randomized to receive first-line chemotherapy, and were used as training and validation sets, respectively...
April 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Susan Halabi, Chen-Yen Lin, W Kevin Kelly, Karim S Fizazi, Judd W Moul, Ellen B Kaplan, Michael J Morris, Eric J Small
PURPOSE: Prognostic models for overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in treatment options available for these patients. This work developed and validated an updated prognostic model to predict OS in patients receiving first-line chemotherapy. METHODS: Data from a phase III trial of 1,050 patients with mCRPC were used (Cancer and Leukemia Group B CALGB-90401 [Alliance])...
March 1, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Susan Halabi, Chen-Yen Lin, Eric J Small, Andrew J Armstrong, Ellen B Kaplan, Daniel Petrylak, Cora N Sternberg, Liji Shen, Stephane Oudard, Johann de Bono, Oliver Sartor
BACKGROUND: Several prognostic models for overall survival (OS) have been developed and validated in men with metastatic castration-resistant prostate cancer (mCRPC) who receive first-line chemotherapy. We sought to develop and validate a prognostic model to predict OS in men who had progressed after first-line chemotherapy and were selected to receive second-line chemotherapy. METHODS: Data from a phase III trial in men with mCRPC who had developed progressive disease after first-line chemotherapy (TROPIC trial) were used...
November 20, 2013: Journal of the National Cancer Institute
Anthony Linton, Greg Pond, Stephen Clarke, Janette Vardy, Matthew Galsky, Guru Sonpavde
BACKGROUND: The modified Glasgow Prognostic Score (mGPS), derived from C-reactive protein (CRP) and albumin levels, and the neutrophil-lymphocyte ratio (NLR) have demonstrated prognostic significance in a number of malignancies. PATIENTS AND METHODS: Baseline mGPS and NLR were calculated in a prospective cohort of chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC) (AT-101-CS-205 trial) who received docetaxel and prednisone ± AT101...
December 2013: Clinical Genitourinary Cancer
Gregory R Pond, Andrew J Armstrong, Brian A Wood, Lance Leopold, Matthew D Galsky, Guru Sonpavde
UNLABELLED: What's known on the subject? and What does the study add? Serum C-reactive protein (C-reactive protein) is emerging as a potential novel prognostic factor in metastatic castration-resistant prostate cancer (mCRPC). In the present study, a prospective trial was investigated retrospectively and a significant prognostic impact for C-reactive protein that was independent of multiple published prognostic models was identified in men receiving docetaxel-based chemotherapy for mCRPC...
December 2012: BJU International
Andrew J Armstrong, Ian F Tannock, Ronald de Wit, Daniel J George, Mario Eisenberger, Susan Halabi
AIMS OF THE STUDY: There are no known predictive factors of response in men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). We investigated pre-treatment factors that predicted a 30% PSA decline (30% PSAD) within 3 months of starting chemotherapy, and assessed performance of a risk group classification in predicting PSA declines and overall survival (OS) in men with mCRPC. METHODS: In TAX327, 1006 men with mCRPC were randomized to receive docetaxel (D) in two schedules, or mitoxantrone (M), each with prednisone: 989 provided data on PSA decline within 3 months...
February 2010: European Journal of Cancer
James L Gulley, Philip M Arlen, Ravi A Madan, Kwong-Yok Tsang, Mary P Pazdur, Lisa Skarupa, Jacquin L Jones, Diane J Poole, Jack P Higgins, James W Hodge, Vittore Cereda, Matteo Vergati, Seth M Steinberg, Susan Halabi, Elizabeth Jones, Clara Chen, Howard Parnes, John J Wright, William L Dahut, Jeffrey Schlom
A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p = 0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC to investigate the influence of GM-CSF with vaccine, and the influence of immunologic and prognostic factors on median OS. Thirty-two patients were vaccinated once with recombinant vaccinia containing the transgenes for prostate-specific antigen (PSA) and three costimulatory molecules...
May 2010: Cancer Immunology, Immunotherapy: CII
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"